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ABSTRACT
Uveal melanoma is a rare disease but it is the most common primary intraocular malignant tumor in 
adults with poor late prognosis. About 50% of patients will develop liver metastasis  far from the 
enucleation within 10-15 years. Our study examined SPANX-C expression levels in primary uveal 
melanoma both with and without metastasis to assess if they can be used to predict metastasis. This 
study included a total of 55 patients, 28 males and 27 females, with uveal melanoma. A 
significantly high expression of SPANX-C was seen in 19/23 (82.6%)  patients with metastasis, and 
only in 11/32 (38.5%) patients without metastasis. In conclusion, we found that SPANX-C 
expression could play a role in tumor progression of uveal melanoma. 
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INTRODUCTION 
Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults and the 
second most common melanoma [1] arising from melanocytes not associated with epithelial 
structures; it has an incidence of 6-7/1,000,000 cases per year and it is considered a rare disease [1] 
with poor late prognosis; about 50% of patients will develop liver metastasis far from the 
enucleation within 10-15 years [2]. Because of this strange behavior, which still has to be netter 
investigated, the authors suggest to search the biological causes to explain late development of liver 
metastasis of uveal melanoma.
The SPANX multigene family includes SPANX-A1/-A2/-B/-C/-D (Human genome build 36.2). 
SPANX-A/D genes are made up of two exons separated by an intron of ≈650 bp and were the first 
SPANX genes described because of their expression in sperm cells [3]. Semiquantitative 
fluorescent multiplex PCR dosage analysis was carried out to identify 16 classes of SPANX-B and 
13 classes of SPANX-C genes [3].
In the literature have been reported immunohistochemical studies on Spanx expression in two 
melanoma cell lines, VMM150 and VMM5, and in the metastatic melanoma tumor from the 
VMM150 cell line. These studies revealed the immunostaining at the nuclear periphery, within the 
nucleoplasm close to the nuclear envelope in the VMM150 cells, while only cytoplasmic staining 
was observed in the VMM5 melanoma cells. In addition, also the tumor cells from which the 
VMM150 cell line was derived were positive at the nuclear level [4]. The variable expression of 
SPANX was also observed in glioblastomas, in which the SPANX-A expression prevails [4]. More 
Recently, immunohistochemical expression of SPANX has been shown in neoplastic cells of 
prostatic cancer with a nuclear/cytoplasmic positivity [5], in testicular neoplasms [6], in particular, 
in seminoma in which the nuclear/cytoplasm staining for SPANX was diffuse and strong, and in 
embryonal carcinomas in which the expression for Spanx was significantly fainter compared with 
both normal and seminoma cells [6,7]. The immunohistochemical expression of SPANX was also 
studied in melanocytic cells, with no staining in normal melanocytes, an intermediate number of 
positive cells in benign nevi and a high percentage of positive cell in cutaneous melanoma, with 
both nuclear and cytoplasm expression [8,9]. 
In the present study, we examined SPANX-C expression levels in 55 primary uveal melanomas, 
both with and without metastasis, and we evaluated their association with other high-risk 
characteristics for metastasis to assess if SPANX-C can be used to predict the behavior of uveal 
melanoma.
PATIENTS AND METHODS
Patients and Tissue Samples
We performed a retrospective analysis of 55 primary choroidal and/or ciliary body melanomas, 
treated by primary enucleation at the Eye Clinic, University of Catania, during the eight years up to 
October 2017. Because of the retrospective nature of the study, no written informed consent from 
patients was obtained. The research protocols were approved by the Local Medical Ethics 
Committee (University of Catania) and conformed to the ethical guidelines of the Declaration of 
Helsinki. Enucleations were performed in cases of tumors not suitable for radiotherapy procedures, 
such as plaque brachytherapy or proton beam radiotherapy.
The patients included 28 men and 27 women; the median age was 67 years (range 29-85). All cases 
of uveal melanomas were evaluated for size and location through ophthalmoscopy and A and B 
scan ultrasonography and presence of metastasis through physical examination, liver ultrasound and 
total body computed tomography. Median follow up period was 60 months (range 8-138 months). 
Forty melanomas involved only the choroid (72.7%), while 15 (27.3%) involved both the choroid 
and the ciliary body; only one case showed extra scleral involvement during surgery, which was 
histologically confirmed. Histologically, 11 (20%) were spindle cell melanomas, 16 (29.2%) 
epithelioid cell melanomas, while 28 (50.8%) were mixed epithelioid and spindle cell melanomas. 
According to the TNM classification, pathological T stage of uveal melanomas with metastasis was: 
pT1a in 1 patient (4.3%), pT2a in 9 patients (39.1%), pT2b in 2 patients (8.7%), pT2d in 1 patient 
(4.3%), pT3a in 4 patients (17.4%), pT3b in 5 patients (21.7%) and pT4a in 1 patient (4.3%); in the 
patients with uveal melanomas without metastasis pathological T stage was: pT1a in 6 patients 
(18.7%), pT1b in 1 patient (3.1%), pT2a in 12 patients (37.5%), pT2b in 6 patients (18.7%), pT3a in 
4 patients (12.5%) and pT4b in 3 patients (9.4%).
Considering the 32 patients with primary uveal melanoma without metastasis, 17 were males and 15 
females; the median age was 64 years (range 29-84). 
Out of the 23 patients with primary uveal melanoma with metastasis, 11 were males and 12 
females; median age was 72 years (range 50-85); 13 of the 23 patients died during follow-up from 
disease progression (tables A,B). 
Formalin-fixed and paraffin-embedded tissue specimens were obtained at the Pathologic Anatomy 
Section, Department G.F. Ingrassia, from section of Anatomic Pathology, GF Ingrassia Department 
of Medical, Surgical, and Advanced Technologies, University of Catania. The following exclusion 
criteria were chosen: 1) paraffin blocks containing the tumor could not be used to obtain additional 
slides for immunohistochemical evaluation, 2) representative tumor tissue was not present in the 
paraffin blocks, 3) the tumor was totally necrotic, 4) the tumor had been treated previously.
Five sections were obtained from paraffin specimens. Briefly, the slides were dewaxed in xylene, 
hydrated using graded ethanols and incubated for 30 min in 0.3% H2O2/methanol to quench 
endogenous peroxidase activity, then rinsed for 20 min with phosphate-buffered saline (PBS; Bio-
Optica, Milan, Italy). The sections were heated (5 min × 3) in capped polypropylene slide-holders 
with citrate buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0; Bio-Optica, Milan, Italy), using a 
microwave oven (750 W) to unmask antigenic sites. To reduce the commonly seen non-specific 
immunoreactivity due to endogenous biotin, sections were pretreated with 10 mg/mL of ovalbumin 
in PBS followed by 0.2% biotin in PBS, each for 15 min at room temperature. Then, the sections 
were incubated overnight at 4 °C with rabbit polyclonal anti-SPANX-C antibody (ab1997; Abcam, 
Cambridge, UK), diluted 1:500 in PBS (Sigma, Milan, Italy). The secondary biotinylated anti-rabbit 
antibody was applied for 30 min at room temperature, followed by the avidin–biotin–peroxidase 
complex (Vector Laboratories, Burlingame, CA, USA) for a further 30 min at room temperature. 
The immunoreaction was visualized by incubating the sections for 4 min in a 0.1% 3,3'-
diaminobenzidine (DAB) and 0.02% hydrogen peroxide solution (DAB substrate kit, Vector 
Laboratories, CA, USA). The sections were lightly counterstained with Mayer’s hematoxylin 
(Histolab Products AB, Göteborg, Sweden) mounted in GVA mountant (Zymed Laboratories, San 
Francisco, CA, USA) and observed with a Zeiss Axioplan light microscope (Carl Zeiss, 
Oberkochen, Germany).
SPANX-C staining was identified as either negative or positive. Immunohistochemical expression 
was assessed as positive when brown chromogen was seen in the nucleus, cytoplasm or cellular 
membrane. Normal testicular tissue was considered as positive control to evaluate the specific 
reaction of primary antibodies. Negative controls, involving the omission of primary antibody, were 
included.
Stain intensity and proportion of immunopositive cells was assessed by light microscopy. Intensity 
of staining (IS) was graded on a scale of 0–3, according to the following assessment: no detectable 
staining = 0, weak staining = 1, moderate staining = 2, strong staining = 3, as described previously 
[10]. The percentage of SPANX-C immunopositive cells (Extent Score, ES) was scored in five 
categories: <5% (0); 5–30% (+); 31–50% (++); 51–75% (+++), and >75% (++++). Counting was 
performed at 200× magnification. Staining intensity was multiplied by the percentage of positive 
cells to obtain the intensity reactivity score (IRS); IRS <6 was considered Low expression (L-IRS), 
IRS >6 was considered High expression (H-IRS).
Immunostained slides were separately evaluated by three pathologists (RC, LP and LS), who were 
blinded to patient identity, clinical status and group identification.
Statistical analysis
Non-parametric comparison of the median values of all parameters in patients without metastasis 
and with metastasis was performed by Kolmogorov-Smirnov test or Fisher’s exact test. Agreement 
among observers was tested by Cohen K. Considering the median of the values of SPANX-C 
detected in all patients, each case was classified into two categories (high and low) that expressed 
SPANX-C higher/equal or lower than the median value. Univariate and multivariate analyses were 
based on a Cox proportional hazards regression model (time free from metastasis as outcome); this 
model included gender, age, melanoma location (choroid or ciliary body), cell type (epithelioid, 
spindle or mixed), extra-scleral extension, pathological T stage, DFS and value of SPANX-C.
All predictors that had a P value <0.15 (cut off) in the univariate analysis were included in the 
multivariate analysis. Survival analysis according to SPANX-C expression levels was performed by 
Kaplan-Meyer test; survival rates were compared by log-rank (Mantel-Cox) test. P values < 0.05 
were considered as statistically significant.
RESULTS 
Immunohistochemistry showed only SPANX-C cytoplasmic staining; SPANX-C was negative in 
non-tumor ocular tissue. Inter-observer agreement was excellent (kappa = 0.944).
In the whole group (n=55) the median SPANX-C value was 4. SPANX-C expression was high in 23 
(41.8%) melanomas, and low in 32 (58.2%) melanomas. 
In 32 primary uveal melanomas without metastasis, SPANX-C IS was strong/moderate in 11 cases 
(34.4%) and weak in 6 cases (18.8%). Fifteen cases (46.9%) were completely negative (Fig. A); ES 
was >50% in 10 cases (31.3%), variable between 5-30% in 7 cases (21.9%). Only 9/32 cases 
(28.1%) showed H-IRS, while the remaining 23 cases showed L-IRS (71.9%). (Fisher’s exact test, 
p=0.009, table D). In 23 primary uveal melanomas with metastasis, SPANX-C IS was 
strong/moderate in 19 cases (82.6%) and weak in 3 cases (13%). Only 1 case (4.3%) was 
completely negative (Fig. B). ES was >75% in 12 cases (52.2%), >50% in 3 cases (13%), 30-50% 
in 6 cases (26.1%), < 30% in 1 case (4.3%). 14/23 cases (60.8%) showed H-IRS, while only 9 cases 
(39.2%) had L-IRS (Fisher’s exact test, p=0.009, table D).
No significant statistical difference was found between primary uveal melanomas with and without 
metastasis and histological subtype (p=0.762). Instead, a significant statistical correlation was found 
among all the patients, disease free survival (p<0.001) and SPANX-C expression (p<0.001) (table 
C).
3.3 Correlations between SPANX expression and clinic-pathological factors in uveal melanomas
Factors related to the presence of metastasis at univariate analysis on a Cox proportional hazards 
regression model were: tumor diameter greater (p=0.057), pT stage (p=0.072), cell type (p=0.005), 
DFS(p=) Thickness (p=), diameter (p=) and SPANX level (p=0.001); at multivariate analysis only 
SPANX level (p=0.004) and histologic type (p=0.003) were significant. 
Comparing histological type and SPANX expression, no correlation was found (Spearman).
Figure C shows the results of the Kaplan–Meier survival analyses in patients with uveal melanomas 
with low and high SPANX expression. The survival times free from metastasis (SE, with 95% CI) 
estimated were respectively: 103.5 (5.0) (CI: 93.8 to 113.3) and 73.6 (12.0) (CI: 50.1 to 97.2).
The log-rank test showed a significant difference between the two groups as regards SPANX 
expression (p=0.001).
DISCUSSION
Uveal melanoma could be considered an ambiguous neoplasia, considering its biological behavior: 
regardless of histological subtype and initial stage, uveal melanoma shows liver metastasis also 
after 10-15 years follow-up.  
In the last few years, many papers, reporting the unexplained behavior of uveal melanoma, have 
compared clinical data and genetic factors, clinical data and protein expression, but to date none has 
resolved the question.
Previously, we reported the prognostic role of ADAM10, RKIP and pRKIP  [10,11], but these 
proteins did not explain the strange behavior of uveal melanoma, thus they may be considered only 
potential prognostic markers.
Salemi et al. studied the SPANX gene family and identified the Xq27 region as responsible for 
genomic rearrangement of deletions, duplication and/or segmental inversions associated with tumor 
growth [9]. Nuclear and/or cytoplasmic SPANX-C expression has been showed in cutaneous 
melanoma [9], testicular embryonal carcinoma [7], prostatic adenocarcinoma [5] and glioblastoma 
[4]. Nevertheless, the role of SPANX in tumor progression of all these tumors is not well 
understood. 
Maine [12] studied SPANX gene expression in a subpopulation of breast cancer cells, defined as 
“trailblazer cells”, able to migrate towards the lung; it has been suggested that tumor cellular 
phenotypes exhibiting SPANX gene expression could be able to spontaneously migrate far from the 
primary tumor, throughout the vascular channels, and modify the extracellular matrix in distant 
organs. Considering the analogy of behavior between lung metastasis from breast cancer and liver 
metastasis from uveal melanoma, we assessed SPANX-C expression in primary uveal melanomas. 
In primary uveal melanoma with metastasis we found mainly moderate/strong cytoplasmic 
SPANX-C expression (82.6%) and H-IRS (60.8%). However, primary uveal melanomas without 
metastasis have shown mainly negative expression (46.9%) and L-IRS (71.9%). Moreover, 
comparing SPANX-C expression in cutaneous melanoma and uveal melanoma, we found a 
different distribution of the protein, mainly nuclear in cutaneous sites and cytoplasmic in uveal 
sites, confirming the different biological behavior of the same tumor phenotype. 
Considering the above results, we investigated a potential relationship between SPANX-C 
expression and tumor progression in uveal melanoma.
It is well known that the SPANX gene has no particular enzymatic functions, but that its interaction 
with other proteins gives it particular characteristics necessary for invasive behavior; in particular, it 
has been shown that the interaction between SPANX-C and Lamin A/C is necessary to provide 
structural stability to the nucleus and proper cellular SPANX-C distribution. SPANX-C 
overexpression in cancer cells has little influence on primary tumor growth, but may be sufficient to 
determine an invasive phenotypes in which cells are able to change the morphology of their 
nucleus, adapt to vessel diameter and exit blood vessels [12].  
In vivo studies have shown that SPANX-C underexpression reduced metastatic behavior of primary 
tumors and the number of potential metastatic cancer cells; moreover, as in vitro studies previously 
reported [12,13], few trailblazer cells could be necessary to select a subpopulation of aggressive 
cancer cells, even if lacking the epithelial-mesenchymal transition (EMT) phenotype that is able to 
develop cellular protrusions into the extra cellular matrix and to autonomously invade metastasize. 
CONCLUSION
SPANX gene overexpression could make the tumor less responsive to target therapy against the 
microenvironment and new therapy preventing the development of trailblazer cells could be 
investigated. Our results confirm the potential role of SPANX-C in tumor behavior: we suppose that 
the assessment of SPANX-C expression in liver metastasis may be useful to confirm and explain 
our data, but unfortunately, at present, we have not the possibility to test SPANX-C expression in 
primary uveal melanoma and liver metastasis. 
REFERENCES 
[1] Y. Yonekawa, I.K. Kim, Epidemiology and management of uveal melanoma, Hematol. 
Oncol. Clin. North. Am. 26 (2012) 1169–1184.  doi: 10.1016/j.hoc.2012.08.004.
[2] Collaborative Ocular Melanoma Study Group, Assessment of metastatic disease status at 
death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma 
Study (COMS): COMS report no. 15, Arch Ophthalmol. 119 (2001) 670–676. 
doi:10.1001/archopht.119.5.670
[3] M. Salemi, A.E. Calogero, R. Castiglione, D. Tricoli, P. Asero, R. Rosa, et al., Expression of 
SpanX proteins in normal  testes and in testicular germ cell tumours, Int. J. Androl. 29 
(2006) 368-373. doi: 10.1111/j.1365-2605.2005.00615.x
[4] V.A. Westbrook, P.D. Schoppee, A.B. Diekman, K.L. Klotz, M. Allietta, K.T. Hogan, et al, 
Genomic organization, incidence, and localization of the SPAN-X family of cancer-testis 
antigens in melanoma tumors and cell lines, Clin. Cancer. Res. 10 (2004) 101-112. doi: 
10.1158/1078-0432.CCR-0647-3.
[5] M. Salemi, A.E. Calogero, G. Zaccarello, R. Castiglione, A. Cosentino, C. Campagna, et al., 
Expression of SPANX proteins in normal prostatic tissue and in prostate cancer, Eur. J. 
Histochem. 54 (2010) e41. doi: 10.4081/ejh.2010.e41
[6] A.J. Zendman, J. Zschocke, A.A. van Kraats,N.J. de Wit, M. Kurpisz, U.H. Weidle, et al, 
The human SPANX multigene family: genomic organization, alignment and expression in 
male germ cells and tumor cell lines, Gene. 309 (2003) 125-133. doi: 10.1016/S0378-
1119(03)00497-9
[7] M. Salemi, A.E. Calogero, P. Bosco, R. Castiglione, S. La Vignera, E. Borgione, et al, 
Expression of SpanX mRNA in testicular germ cell tumors, Hum. Cell. 19 (2006) 87-90. 
doi: 10.1111/j.1749-0774.2006.00014.x
[8] M. Salemi, A.E. Calogero, E. Vicari, E. Migliore, G. Zaccarello, A. Cosentino, et al, A high 
percentage of skin melanoma cells expresses SPANX proteins, Am. J. Dermatopathol. 31 
(2009) 182-186. doi: 10.1097/DAD.0b013e3181978d6f.
[9] M. Salemi, P. Bosco, F. Calì, A.E. Calogero, P.F. Soma, A. Galia, et al., SPANX-B and 
SPANX-C (Xq27 region) gene dosage analysis in Sicilian patients with melanoma, 
Melanoma Res. 18 (2008) 295-299. doi: 10.1097/CMR.0b013e32830aaa90
[10] R. Caltabiano, L. Puzzo, V. Barresi, A. Ieni, C. Loreto, G. Musumeci, et al, ADAM 
10 expression in primary  uveal melanoma as prognostic factor for risk of metastasis, Pathol. 
Res. Pract. 212 (2016) 980-987. doi: 10.1016/j.prp.2016.08.003.
[11] R. Caltabiano, L. Puzzo, V. Barresi, V. Cardile, C. Loreto, M. Ragusa, et al, 
Expression of Raf Kinase Inhibitor Protein (RKIP) is a predictor of uveal melanoma 
metastasis, Histol. Histopathol. 29 (2014) 1325-1334. doi: 10.14670/HH-29.1325.
[12] E.A. Maine, J.M. Westcott, A.M. Prechtl, T.T. Dang, A.W. Whitehurst, G.W. 
Pearson, The cancer-testis antigens SPANX-A/C/D and CTAG2 promote breast cancer 
invasion, Oncotarget. 7 (2016) 14708-14726. doi: 10.18632/oncotarget.7408.
[13] J.M. Westcott, A.M. Prechtl, E.A. Maine, T.T. Dang, M.A. Esparza, H. Sun, et al, 
An epigenetically distinct breast cancer cell subpopulation promotes collective invasion, J. 
Clin. Invest. 125 (2015) 1927-1943. doi: 10.1172/JCI77767.
Figure Legends
Fig. A
SPANX-C immunohistochemical expression in uveal melanomas without metastasis.
1) Tumor cells are completely negative; 2) Melanoma cells show a weak positivity for SPANX-C 
(IS 1); 3 and 4 revealed, respectively, a moderate (IS 2) and strong (IS 3) immunoreactivity.
Fig. B
SPANX-C immunohistochemical expression in uveal melanomas with metastasis.
1) Tumor cells are completely negative; 2) Melanoma cells show a weak positivity for SPANX-C 
(IS 1); 3 and 4 revealed, respectively, a moderate (IS 2) and strong (IS 3) immunoreactivity.
Fig. C 





Table A. Demographics, tumour parameters, disease free time, follow-up and SPANX expression in primary uveal melanoma without metastasis.
SPANX













(months) IS ES IRS
F 29 choroid 14,2 16,2 mixed N pT2a 138 138 3 4 12 H
F 83 choroid/cil.body 14,84 16,8 mixed N pT2b 123 123 0 0 0 L
F 55 choroid 9,8 13,9 spindle N pT2a 122 122 0 0 0 L
F 30 choroid/cil.body 12,05 9,2 spindle N pT2b 122 122 2 1 2 L
M 74 choroid/cil.body 10,04 16,1 spindle N pT2b 121 121 3 4 12 H
M 64 choroid 7,7 11,5 spindle N pT1a 112 112 2 4 8 H
F 36 choroid 5,81 12,7 spindle N pT1a 109 109 1 1 1 L
F 59 choroid 8,4 16,7 mixed N pT2a 108 108 1 1 1 L
M 36 choroid 6,47 9,8 mixed N pT1a 108 108 1 3 3 L
M 84 choroid/cil.body 11,9 14,8 mixed N pT2b 106 106 0 0 0 L
F 67 choroid 10,42 13.02 mixed N pT3a 105 105 1 1 1 L
M 73 choroid 9,7 11,3 mixed N pT2a 102 102 1 1 1 L
F 45 choroid 13,7 10,2 mixed N pT2a 96 96 1 1 1 L
M 58 choroid 13,1 14,3 mixed N pT2a 96 96 0 0 0 L
M 63 choroid 3,3 11,7 spindle N pT2a 85 85 0 0 0 L
M 54 choroid 6,32 10 spindle N pT2a 83 83 0 0 0 L
F 84 choroid 11,7 17,4 mixed N pT3a 78 78 0 0 0 L
M 73 choroid 9,24 17,7 epithelioid N pT2a 72 72 0 0 0 L
M 83 choroid 10,62 9,4 epithelioid N pT3a 72 72 3 4 12 H
F 71 choroid 3,68 06.04 epithelioid N pT1a 71 71 0 0 0 L
M 55 choroid/cil.body 7,5 08.09 epithelioid N pT2b 61 61 0 0 0 L
M 52 choroid 9,2 12,1 spindle N pT2b 60 60 3 4 12 H
M 46 choroid 8,76 11,3 spindle N pT2a 54 54 3 4 12 H
F 76 choroid 8,02 10,7 mixed N pT1a 48 48 2 4 8 H
F 63 choroid 10,3 13,7 mixed N pT2a 42 42 0 0 0 L
F 41 choroid 5,85 10,3 mixed N pT1a 42 42 0 0 0 L
F 55 choroid 3,2 7,6 mixed N pT2a 24 24 2 4 8 H
F 74 choroid 8,6 10,2 mixed N pT4b 24 24 0 0 0 L
M 68 choroid/cil.body 10,1 10,1 epithelioid N pT1b 24 24 0 0 0 L
M 74 choroid/cil.body 14,45 17,5 epithelioid N pT4b 18 18 0 0 0 L
M 70 choroid/cil.body 16,27 20,8 spindle N pT4b 12 12 2 1 2 L
M 66 choroid 9,2 14,1 mixed N pT3a 12 12 3 3 9 H
Tab. A Abbreviations: DFS, disease free survival; SPANX; cil.body, ciliary body. 
Table B. Demographics, tumour parameters, disease free time, follow-up and SPANX expression in primary uveal melanoma with metastasis.
SPANX













(months) IS ES IRS
F 58 choroid 6,04 17,8 mixed N pT2a 63 64 (†) 3 4 12 H
M 69 choroid 7,21 15,8 mixed N pT2a 54 81 (†) 3 4 12 H
F 75 choroid/cil.body 15,5 15,3 mixed N pT3b 44 62 (†) 3 4 12 H
F 50 choroid 7,36 15,6 epithelioid N pT2a 41 81 3 4 12 H
M 62 choroid 13,68 16 mixed N pT3a 38 51 (†) 2 3 6 H
F 51 choroid/cil.body 11,4 18,5 mixed N pT3b 38 61 2 2 4 L
M 71 choroid 13,14 17,1 epithelioid N pT3a 33 34 (†) 2 4 8 H
M 76 choroid/cil.body 11,6 6,5 mixed N pT1a 31 39 3 4 12 H
M 72 choroid 10,3 15,4 mixed N pT3b 27 35 (†) 1 3 3 L
F 85 choroid/cil.body 7,3 14,7 spindle Y pT2d 26 49 (†) 3 3 9 H
M 73 choroid 5,73 11,7 epithelioid N pT2a 26 42 (†) 3 4 12 H
F 51 choroid 9,42 19 mixed N pT3a 25 39 2 2 4 L
F 74 choroid 5,7 12,1 spindle N pT2a 24 37 (†) 3 4 12 H
F 67 choroid 3,49 20 mixed N pT4a 24 31 (†) 0 0 0 L
M 74 choroid 11,35 10,5 epithelioid N pT3a 19 47 2 2 4 L
M 82 choroid 9,7 11 epithelioid N pT2a 19 42 3 4 12 H
F 72 choroid 6,7 15,2 epithelioid N pT2a 14 28 (†) 2 2 4 L
M 76 choroid 13,7 17,1 mixed N pT2a 14 70 1 1 1 L
M 79 choroid 13,91 16,1 epithelioid N pT3b 13 38 3 4 12 H
F 66 choroid/cil.body 8,95 12,5 mixed N pT2b 12 37 (†) 2 2 4 L
F 60 choroid 8,25 16,5 epithelioid N pT2a 11 37 (†) 3 4 12 H
F 57 choroid/cil.body 13,6 19 epithelioid N pT2b 6 55 1 2 2 L
M 72 choroid/cil.body 13,3 15,4 mixed N pT3b 0 51 3 4 12 H
Tab. B Abbreviations: DFS, disease free survival; SPANX; cil.body, ciliary body. (†) death











































































































p (metastasis free vs 
metastasis) 0.400* 0.762 ° 0.911* 0.007 * 0.400 * 0.418° 0.560* <0.001* 0.001 * <0.001*
Tab. C
 * Kolmogorov-Smirnov test
 ° Fisher’s exact test
Table D. Number of uveal melanoma (with and without metastasis) with low and high SPANX
Metastasis (n=23) Metastasis free (n=32)
Low 9 (39.1%) * 23 (71.9%)
High 14 (60.9%) 9 (28.1%)
Tab.D Abbreviations: SPANX.
p (Fisher’s exact test)
* p=0.026
